Skip to main content

Table 1 Correlations between clusterin expression and clinicopathologic parameters and univariate analysis of survival in pancreatic adenocarcinoma

From: Clinical significance of clusterin expression in pancreatic adenocarcinoma

Parameter

Number of cases (%)

Clusterin expression

Survival analysis

  

Clusterin-positive cases (%)

P value

Median survival (months)

P value

Overall

52 (100.0)

17 (32.7)

 

14.9

 

Age

  

0.780

 

0.029

 ≥65 years

35 (67.3)

11 (31.4)

 

10.4

 

  < 65 years

17 (32.7)

6 (35.3)

 

38.7

 

Sex

  

0.747

 

0.792

 Male

37 (71.2)

13 (35.1)

 

15.0

 

 Female

15 (28.8)

4 (26.7)

 

10.4

 

Tumor size

  

0.241

 

0.075

 ≤2 cm

9 (17.3)

1 (11.1)

 

35.4

 

  > 2 cm

43 (82.7)

16 (37.2)

 

14.7

 

Location

  

0.413

 

0.648

 Head

44 (84.6)

13 (29.5)

 

15.0

 

 Body/tail

8 (15.4)

4 (50.0)

 

9.9

 

Pathologic grade

  

0.711

 

0.010

 Well/moderately differentiated

42 (80.8)

13 (31.0)

 

15.9

 

 Poorly differentiated/anaplastic

10 (19.2)

4 (40.0)

 

3.1

 

Perineural invasion

  

0.042

 

0.414

 No

8 (15.4)

0 (0.0)

 

18.5

 

 Yes

44 (84.6)

17 (32.7)

 

11.5

 

Lymphovascular invasion

  

0.330

 

0.055

 No

15 (28.8)

3 (20.0)

 

39.6

 

 Yes

37 (71.2)

14 (37.8)

 

8.9

 

Preoperative CEA (ng/ml)

  

0.048

 

0.787

 ≤5

32 (69.6)

8 (25.0)

 

15.0

 

  > 5

14 (30.4)

8 (57.1)

 

14.7

 

Preoperative CA19-9 (U/ml)

  

1.000

 

0.640

 ≤37

15 (33.3)

5 (33.3)

 

15.9

 

  > 37

30 (66.7)

10 (33.3)

 

16.5

 

Lymph node metastasis

  

0.006

 

0.002

 No

16 (31.4)

1 (6.3)

 

39.7

 

 Yes

35 (68.6)

16 (45.7)

 

9.9

 

Clusterin expression

  

–

 

0.312

 Negative

35 (67.3)

–

 

15.0

 

 Positive

17 (32.7)

–

 

14.9

 
  1. CA19-9, carbohydrate antigen 19-9; CEA, carcinoembryonic antigen.